Accelerating drug development with synthetic biology and next-generation sequencing
We are a team of synthetic biologists and next-generation sequencing experts focused on disrupting the way that pharmaceutical companies discover, optimize, and characterize drugs.
Central to our vision is AlphaSeq, the leading technology for quantitative, multi-target characterization of biologics and small molecules that modulate protein interactions.
A-Alpha Bio, Inc. was founded in 2017 as a spinout from the University of Washington's Institute for Protein Design and Center for Synthetic Biology.
David co-invented AlphaSeq while working on his PhD in Bioengineering at the University of Washington with scientific advisors David Baker and Eric Klavins. He is an expert in developing and optimizing high-impact technologies by combining genetic engineering and next-generation sequencing.
Randolph received his PhD in Bioengineering from the University of Washington. Before UW, he was a Process Development Engineer at Illumina where he was responsible for improving quality control efficiency and translating products into manufacturing. Since then, he has expanded his expertise into synthetic biology and computer science.
Dr. Eric Klavins, PhD
Professor, UW Electrical Engineering
Director, UW Center for Synthetic Biology
Director, UW BIOFAB
Dr. David Baker, PhD
Professor, UW Biochemistry & HHMI
Director, UW Institute for Protein Design
Member, NAS & AAS
Dr. Lance Stewart, PhD, MBA
CSOO, UW Institute for Protein Design
Co-founder, Beryllium Discovery & Northwest NeuroNeighborhood
Founder & CEO, Octavia & Cadence Biomedical
Advisor, Jones & Foster Accelerator Program